MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 177 ($2.33) and last traded at GBX 202.77 ($2.67), with a volume of 418041 shares trading hands. The stock had previously closed at GBX 192 ($2.53).
MaxCyte Price Performance
The company has a market capitalization of £267.66 million, a price-to-earnings ratio of -7.43 and a beta of 1.13. The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The company’s 50 day simple moving average is GBX 258.95 and its 200-day simple moving average is GBX 294.59.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Articles
- Five stocks we like better than MaxCyte
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Beware of BigBear.ai: Insiders Are Selling—Should You?
- What Are Dividend Challengers?
- CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
- What is the MACD Indicator and How to Use it in Your Trading
- Congress! Who Traded What During the Tariff-Induced Meltdown
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
